HDAC6 and Ovarian Cancer

被引：27

作者：

Haakenson, Joshua ^{[1
]}

Zhang, Xiaohong ^{[1
,2
]}

机构：

[1] Univ S Florida, Morsani Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2013年 / 14卷 / 05期

关键词：

HDAC6; ovarian cancer; cancer-related signaling pathways; inhibitors; cell stress response; motility; oncogenesis; histone deacetylase; HISTONE DEACETYLASE 6; REGULATES AGGRESOME FORMATION; 2 CATALYTIC DOMAINS; CELL-MIGRATION; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; STRESS GRANULES; PROTEIN; TUBULIN; INHIBITORS;

D O I：

10.3390/ijms14059514

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways. Many of the lessons learned from other cancers can be applied to ovarian cancer as well. HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions. Not all pro-cancer interactions of HDAC6 involve deacetylation. The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.

引用

页码：9514 / 9535

页数：22

共 50 条

[41] Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
Bazzaro, Martina
Lin, Zhenhua
Santillan, Antonio
Lee, Michael K.
Wang, Mei-Cheng
Chan, Kwun C.
Bristow, Robert E.
Mazitschek, Ralph
Bradner, James
Roden, Richard B. S.
CLINICAL CANCER RESEARCH, 2008, 14 (22) : 7340 - 7347
[42] Carbenoxolone disodium suppresses the migration of gastric cancer by targeting HDAC6
Song, Zhiyu
Zhao, Chenglong
Yan, Jingjing
Jiang, Dandan
Jia, Gang
FUTURE MEDICINAL CHEMISTRY, 2023, 15 (04) : 333 - 344
[43] Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells
Rosik, Lorena
Niegisch, Guenter
Fischer, Ute
Jung, Manfred
Schulz, Wolfgang Arthur
Hoffmann, Michele Janine
CANCER BIOLOGY & THERAPY, 2014, 15 (06) : 742 - 757
[44] HDAC6 IS A NOVEL REGULATOR OF MTOR ACTIVITY IN COLORECTAL CANCER CELLS
Zhou, Yuning
Wang, Qingding
Weiss, Heidi L.
Evers, B. Mark
GASTROENTEROLOGY, 2018, 154 (06) : S874 - S874
[45] The role of histone deacetylase 6 (HDAC6) in neurodegeneration
Van Helleputte, Lawrence
Benoy, Veronick
Van Den Bosch, Ludo
RESEARCH AND REPORTS IN BIOLOGY, 2014, 5 : 1 - 13
[46] HDAC6 is a microtubule-associated deacetylase
Hubbert, C
Guardiola, A
Shao, R
Kawaguchi, Y
Ito, A
Nixon, A
Yoshida, M
Wang, XF
Yao, TP
NATURE, 2002, 417 (6887) : 455 - 458
[47] HDAC6 distribution in amyotrophic laterals sclerosis
Van Weehaeghe, D.
Koole, M.
De Vocht, J.
Gilbert, T. M.
Schroeder, F. A.
Kranz, J. E.
Hooker, J. M.
Van Damme, P.
Van Laere, K.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S96 - S97
[48] Inhibitors selective for HDAC6 in enzymes and cells
Gupta, Praveer K.
Reid, Robert C.
Liu, Ligong
Lucke, Andrew J.
Broomfield, Steve A.
Andrews, Melanie R.
Sweet, Matthew J.
Fairlie, David P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) : 7067 - 7070
[49] Ricolinostat is not a highly selective HDAC6 inhibitor
Guillaume Médard
Jason M. Sheltzer
Nature Cancer, 2023, 4 : 807 - 808
[50] A Role Of Hdac6 In A Model Of Lung Fibrosis
Saito, S.
Zhuang, Y.
Shan, B.
Sanchez, C. G.
Lasky, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187

← 1 2 3 4 5 →